Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 4, 2013, Pages 900-906

  Muller, Anouk E ^a,b,c   Punt, Nieko ^d   Mouton, Johan W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CPRLab   (Netherlands)

^d Medimatics   (Netherlands)

Author keywords

lactam antibiotics; Effectivity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CEFTAZIDIME; CEFTOBIPROLE; LINEZOLID;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CEFTAZIDIME; COHORT STUDIES; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875273480     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks468     Document Type: Article

References (14)

1. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
2. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
3. Mouton JW, Punt N, Vinks AA. Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo. Antimicrob Agents Chemother 2007; 51: 3449-51.
4. Mouton JW, Brown DF, Apfalter P et al. The role of pharmacokinetics/ pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012; 18: E37-45.
5. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
6. Bhavnani SM, Forrest A, Hammel JP et al. Pharmacokineticspharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 62: 99-101.
7. Ambrose PG, Grasela DM, Grasela TH et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45: 2793-7.
8. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
9. Mouton JW, Horrevorts AM, Mulder PG et al. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers. Antimicrob Agents Chemother 1990; 34: 2307-11.
10. Buijk SL, Gyssens IC, Mouton JW et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002; 49: 121-8.
11. Mouton JW, Jacobs N, Tiddens H et al. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005; 52: 123-7.
12. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.
13. Meagher AK, Passarell JA, Cirincione BB et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007; 51: 1939-45.
14. Passarell JA, Meagher AK, Liolios K et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008; 52: 204-10.